NASDAQ
Versartis Reports Fourth Quarter 2016 Financial Results
MENLO PARK, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused ...
CytomX Therapeutics to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...
Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th
REDWOOD CITY, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today ...
ICU Medical, Inc. Announces Time of Fourth Quarter and Fiscal Year 2016 Earnings Conference Call
SAN CLEMENTE, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a ...
PharmaCyte Biotech Discusses Patient Enrollment and TD2’s Role in Upcoming Clinical Trial
LAGUNA HILLS, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a ...
Lumenis is Proud to Support the First International Scar Treatment Conference in Israel
YOKNEAM, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Lumenis Ltd., the world’s largest energy-based ...
Lumenis is Proud to Support the First International Scar Treatment Conference in Israel
YOKNEAM, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Lumenis Ltd., the world’s largest energy-based ...
JACC: Clinical Electrophysiology Manuscript Featuring BioSig’s PURE EP System in Top Five Most Influential of 2016
Minneapolis, MN, Feb. 21, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device ...
RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
Top-line results are expected in the second quarter of 2017 The randomized, double-blind, placebo-controlled Phase III study ...
XBiotech Reports Affirmative Interim Analysis of Global Phase 3 Colorectal Cancer Study
AUSTIN, Texas, Feb. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced that ...
XBiotech Reports Affirmative Interim Analysis of Global Phase 3 Colorectal Cancer Study
AUSTIN, Texas, Feb. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced that ...
RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
Top-line results are expected in the second quarter of 2017 The randomized, double-blind, placebo-controlled Phase III study ...
